The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Company (EMA) has given a sure belief for Blenrep (belantamab mafodotin) for the treatment of relapsed or refractory a pair of myeloma. The drug is an antibody drug conjugate comprising a humanized IgG1κ monoclonal antibody focusing on the B-cell maturation antigen (BCMA…
Read Extra
Blenrep Will get European Nod to Take care of A pair of Myeloma
You May Also Like
Posted in
European
European markets damage files for solar production in April
Posted by
News Author
More From Author
Posted in
Main
FTC’s ‘click to waste’ subscription principles thrown out by judges
Posted by
News Author
Posted in
Main
Perplexity debuts Comet, a free AI browser (that currently charges $200)
Posted by
News Author